Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Lansoprazole DR Orally Disintegrating Tablets a therapeutic equivalent generic version of Prevacid SoluTab Delayed Release Orally Disintegrating Tablets, 15 mg and 30 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.
Dr. Reddy's Lansoprazole DR Orally Disintegrating Tablets are available in 15 mg and 30 mg tablets in unit-dose packages of 100 (10 x 10).
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4685.15 as compared to the previous close of Rs. 4617.85. The total number of shares traded during the day was 79429 in over 6618 trades.
The stock hit an intraday high of Rs. 4725 and intraday low of 4530.05. The net turnover during the day was Rs. 366762173. |
